Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Duration for Pulmonary Tuberculosis in HIV Infection
NCT00001033Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isoniazid and rifampicin in pulmonary tuberculosis (TB) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Combined rate of failure during therapy and relapse after therapy at 2 years. Status: completed.
02
Drugs
isoniazidrifampicin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT00001033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001033.